Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

IF 2.5 4区医学 Q3 ONCOLOGY

Current Problems in Cancer Pub Date : 2023-09-27 DOI:10.1016/j.currproblcancer.2023.101017

Muhammet Ali Kaplan , Mehmet Ali Nahit Şendur , Ayten Kayı Cangır , Pınar Fırat , Erdem Göker , Saadettin Kılıçkap , Başak Oyan , Ayşim Büge Öz , Feyyaz Özdemir , Gökhan Özyiğit

{"title":"Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group","authors":"Muhammet Ali Kaplan , Mehmet Ali Nahit Şendur , Ayten Kayı Cangır , Pınar Fırat , Erdem Göker , Saadettin Kılıçkap , Başak Oyan , Ayşim Büge Öz , Feyyaz Özdemir , Gökhan Özyiğit","doi":"10.1016/j.currproblcancer.2023.101017","DOIUrl":null,"url":null,"abstract":"<div><p>Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.</p></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"47 6","pages":"Article 101017"},"PeriodicalIF":2.5000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0147027223000703/pdfft?md5=e62c7ae8a65347014efe3625160d7c78&pid=1-s2.0-S0147027223000703-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027223000703","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.

查看原文本刊更多论文

胸膜间皮瘤的既定和新的治疗路线图：土耳其合作小组的意见。

胸膜间皮瘤（PM）是一种胸膜表面的癌症，具有侵袭性，可能迅速致命。PM是全球罕见的癌症，但在土耳其是一种相对常见的疾病。石棉暴露是该疾病的主要危险因素和最常见的潜在原因。许多恶性肿瘤的诊断和治疗都有了显著的改进；然而，PM仍然存在治疗挑战。在这篇综述中，我们旨在通过强调PM患者未满足的需求，并强调对PM进行多学科治疗和管理的必要性，提高卫生保健专业人员、肿瘤学家和肺科医生的认识。在回顾了有关PM的一般信息后，我们进一步讨论了使用免疫疗法治疗PM患者的选择，并为这些新的治疗方式改善这些患者的临床结果提供了证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Cancer 医学-肿瘤学

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

15 days

期刊介绍： Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.